TIAA CREF Investment Management LLC Has $1.82 Million Holdings in Meridian Bioscience Inc. (VIVO)
TIAA CREF Investment Management LLC grew its holdings in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 1.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 115,208 shares of the company’s stock after acquiring an additional 1,294 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.27% of Meridian Bioscience worth $1,815,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in VIVO. State of Alaska Department of Revenue raised its stake in shares of Meridian Bioscience by 77.5% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock worth $130,000 after buying an additional 3,613 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Meridian Bioscience by 3.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock worth $157,000 after buying an additional 370 shares in the last quarter. OppenheimerFunds Inc. bought a new stake in shares of Meridian Bioscience in the 1st quarter worth $161,000. UBS Asset Management Americas Inc. bought a new stake in shares of Meridian Bioscience in the 1st quarter worth $179,000. Finally, Leucadia National Corp bought a new stake in shares of Meridian Bioscience in the 2nd quarter worth $197,000. Institutional investors own 87.24% of the company’s stock.
A number of research firms have recently commented on VIVO. Zacks Investment Research downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $14.00 price objective on shares of Meridian Bioscience in a research note on Friday, October 13th. Three investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $14.00.
In related news, Chairman John A. Kraeutler purchased 7,000 shares of Meridian Bioscience stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the transaction, the chairman now directly owns 345,230 shares of the company’s stock, valued at $4,719,294.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.30% of the stock is owned by company insiders.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.